Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias
A new engineered immune booster paired with CAR-T cells shows stronger anti-tumor effects in early studies, potentially improving cell therapy outcomes.
Epitope-directed nanobody discovery platform identified Nb479, a potent gp34-mimicking OX40 agonist; trimerized Nb479 conjugated with anti-serum albumin nanobody shows improved pharmacokinetics and enhanced anti-tumor activity in combination with CD19 CAR-T cells in vivo. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- experimental_preclinical
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
First report of a genuinely potent OX40 agonist nanobody with validated in vivo activity; OX40 has been a high-priority but clinically intractable immunotherapy target; platform addresses discovery biases preventing prior successes; J Immunother Cancer by a leading hematology/immunotherapy group; patent filed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.